BioGENEius Challenge Announces 2019 BioGENEius Hall of Fame Awardee
WASHINGTON–(BUSINESS WIRE)–Today, the Biotechnology Institute announced the winner of the BioGENEius Hall of Fame Award, who will be recognized next…
Pharmaceuticals, Biotechnology and Life Sciences
WASHINGTON–(BUSINESS WIRE)–Today, the Biotechnology Institute announced the winner of the BioGENEius Hall of Fame Award, who will be recognized next…
LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, will present updated interim results from a Phase II clinical…
Data presented at ASCO 2019 showed 57% of patients alive at three years vs. 43.5% on placebo WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca…
DCVAC/LuCa decreased the risk of death in patients with stage IV NSCLC by 46% Median overall survival (OS) reached 15.5…
22% of Patients Receiving LYNPARZA Remained Progression-Free After Two Years vs. 10% on Placebo, Following Platinum-Based Chemotherapy AstraZeneca and Merck’s…
New technology innovations mark the company’s next milestones, and build on its pioneering history ATLANTA–(BUSINESS WIRE)–SCIEX, a global leader in…
LISBON, Portugal–(BUSINESS WIRE)–Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today presented topline results…
BOSTON & LOUISVILLE, Ky.–(BUSINESS WIRE)–Talaris Therapeutics, Inc., a privately held biotechnology company developing transformative cell therapies that have the potential…
— Data Show High Rates of Response to Single Infusion of KTE-X19 — — Phase 2 Portion of ZUMA-3 is…
Tumor regressions demonstrate potential for DPX-Survivac immunotherapy in hard-to-treat solid tumors Data correlations of survivin specific T cell levels and…